Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
SPARK has extended its influence to an additional 9.47 million students worldwide
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Subscribe To Our Newsletter & Stay Updated
